A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants

NCT07671391 · Not yet recruiting

Last updated 2026-07-14

This clinical trial is testing whether an injection called LAE102, combined with the drug tirzepatide, affects body composition in adults with obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-08 · est. completion 2027-12

What this study is testing ClinicalTrials.gov NCT07671391 ↗

Description as written by the study sponsor.

This study is a randomized, double-blind, placebo-controlled trial aimed at exploring the effects of LAE102 injection in combination with Tirzepatide on body composition.

Treatments tested

LAE102 +Tirzepatide Drug

Receive LAE102, once a week, by subcutaneous injection.The dosage of Tirzepatide starts at lower dose, administered subcutaneously once a week, and is gradually increased every 4 weeks.
LAE102 placebo,+Tirzepatide Drug

Receive the LAE102 placebo, once a week, by subcutaneous injection. The dosage of Tirzepatide starts at lower dose, administered subcutaneously once a week, and is gradually increased to a higher dose level every 4 weeks.

Main thing measured	The percentage change in lean body mass
Sponsor	Shanghai Zhongshan Hospital
Conditions studied	Obesity Adult Onset
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07671391 ↗